Kodiak Sciences rises after eye-disease drugs meet late-stage trial goals

** Shares of drug developer Kodiak Sciences KOD.O jump 141.1% to $78, hitting highest level in more than four years

** Stock set for biggest daily percentage rise ever, if gains hold

** Co says its experimental drugs Zenkuda and tabirafusp-ted met the main goals of a late-stage trial in patients with wet age-related macular degeneration

** Both drugs achieved vision gains at one year that were not inferior to aflibercept, the comparison treatment

** Wet age-related macular degeneration causes abnormal blood vessels to leak beneath the retina and can lead to loss of central vision

** About 54% of Zenkuda patients reached a six-month dosing interval, potentially reducing the number of eye injections needed

** Both drugs showed safety broadly consistent with aflibercept; Kodiak plans further analyses to identify which patients may benefit most from tabirafusp-ted

** Co plans to seek US approval for Zenkuda in Q4 2026, using results from five successful late-stage studies across three retinal diseases

** Including session's move, KOD up 174.4% YTD